Is ResearchGate Legit in 2026? An Evidence-Based Review

Ask ten researchers whether ResearchGate is worth their time and you will get ten different answers, most of them strongly held and few of them supported by evidence. This review is an attempt to fix that. It draws on peer-reviewed studies, the public legal record of the Elsevier and ACS lawsuits, ResearchGate's current publisher partnerships, and the 2023 MDPI controversy that caused real researchers to leave the platform.

The short answer: ResearchGate is legally legitimate, has measurable visibility benefits for most researchers, and has genuine problems around its metrics and signal quality. The long answer is below, and it is more nuanced than either the platform's marketing or its critics usually allow.

What the Peer-Reviewed Evidence Actually Says

Most claims that "ResearchGate boosts citations" come from ResearchGate's own marketing materials. A smaller number of independent peer-reviewed studies have actually measured the relationship. Based on articles retrieved from PubMed, here is what they found.

2,210 nursing articles, Scopus citations 2016–2021

A cross-sectional study published in the Journal of Nursing Scholarship analysed 2,210 articles from top nursing journals and tracked their Scopus citations through 2021. After controlling for author count, funding, open access status, international collaboration, and tweet count, the percentage of authors with a ResearchGate account was positively and independently associated with citation count (Tang et al., 2022, DOI: 10.1111/jnu.12827).

A less-discussed finding from the same study: the median percentage of authors with ResearchGate accounts was 75%. In nursing, ResearchGate is already saturated. The strategic implication is that not having an account becomes the deviation, not having one the advantage.

Iranian highly-cited clinicians, 55 papers

A 2018 scientometrics study in the Journal of Education and Health Promotion examined 55 highly-cited clinical medicine papers from Iran, covering 107 authors. Authors were checked against four networks: ResearchGate, Academia.edu, Mendeley, and LinkedIn. ResearchGate had the highest adoption at 64.5%. The authors reported a positive relationship between network visibility and both citation counts and h-index, with significant correlations between RG-specific metrics (score, reads, views) and Scopus citations (Ramezani-Pakpour-Langeroudi et al., 2018, DOI: 10.4103/jehp.jehp_69_17).

Important caveat: the sample was pre-selected for being highly cited. These researchers would have been cited regardless of ResearchGate. The study cannot rule out reverse causation — that citable researchers happened to join ResearchGate — nor does it randomise the intervention.

Kashan University of Medical Sciences, 533 articles

A 2016 study in Electronic Physician cross-referenced 533 Scopus-indexed articles from Kashan University with their ResearchGate and Mendeley entries. ResearchGate covered 74% of the articles; Mendeley covered 44%. A Spearman correlation found that the number of ResearchGate views was positively correlated with Scopus citation counts (Batooli et al., 2016, DOI: 10.19082/2048).

The common limitation across all three

All three studies are observational. None randomised who got a ResearchGate account. None used instrumental variables to identify causal effects. The consistent finding — that ResearchGate-active authors get cited more — is fully compatible with a simpler explanation: researchers who bother to maintain ResearchGate profiles are the same researchers who bother to do everything else that generates citations. They network, they tweet, they share preprints, they deposit in institutional repositories, they update their Google Scholar profiles.

This is the single most important caveat in the entire evidence base for academic social networks. It is almost never mentioned in ResearchGate's own marketing materials.

The Metrics Problem: RG Score and the RI Score

ResearchGate's internal metrics have a complicated history that matters if you ever considered citing them in a CV, dossier, or grant application.

The RG Score is dead

ResearchGate phased out the original RG Score in August 2022. A 2024 analysis in Open Information Science identified three reasons the score failed (DOI: 10.1515/opis-2024-0011):

• Opacity. The calculation formula was never publicly disclosed. Independent verification was impossible.
• Inflation. The score could be amplified through excessive Q&A participation, which is not a productivity signal in any conventional sense.
• No negative weighting. Retractions, predatory publishing, and other misconduct signals did not reduce the score.

If you have an old CV or website that mentions your RG Score, remove it. The metric no longer exists and citing it signals that you have not updated your profile in four years.

The Research Interest Score has its own problems

The Research Interest (RI) Score replaced the RG Score. It uses four weighted factors: citations (0.5), recommendations (0.25), full-text reads (0.15), and other reads (0.05). It is more transparent than its predecessor. It still has documented limitations.

The 2024 Open Information Science analysis flagged that the RI Score can only increase. There is no mechanism to penalise retractions, predatory-journal activity, or other negative signals. ResearchGate also provides no rationale for the specific weightings it chose.

More concerning: a 2025 study of 835 academic sports medicine orthopaedic surgeons in the US, published in the Orthopaedic Journal of Sports Medicine, found that RI Score and h-index both increased with academic rank but were not correlated with each other (Clausen et al., 2025, DOI: 10.1177/23259671251351331). The study's authors concluded that "further research is warranted on its validity as a productivity measure before its inclusion for academic promotion."

The practical implication: RI Score measures something, but what it measures is not the same thing as the h-index. Do not include your RI Score in a tenure or promotion dossier. It is unvalidated.

The Legal Story: Why ResearchGate Was Risky, and Why It Isn't Anymore

If you joined ResearchGate before 2023, you lived through years of confusion about whether uploading your own papers was legal. The confusion has ended. Here is the actual timeline.

2017: Elsevier and ACS sue in Germany

The American Chemical Society and Elsevier filed a copyright infringement lawsuit against ResearchGate in Germany in 2017, alleging mass-scale infringement. A second suit was filed in the United States in 2018.

2021: 200,000 papers removed

ResearchGate removed approximately 200,000 papers at the request of ACS and Elsevier. Publishers argued that the takedown-notice process was "disruptive and unsustainable" and pushed for a technical solution that would check copyright at the point of upload.

2022: Munich court rules against ResearchGate

A Munich court ruled that ResearchGate is responsible for infringing content on its platform. The court dismissed the publishers' specific damages claims because the publishers had not proven they owned the relevant rights, but the underlying finding on platform liability stood (Nature, 2022).

September 2023: The settlement

On 15 September 2023, ACS, Elsevier, and ResearchGate announced a joint settlement. The agreement introduced automated copyright checks at the point of upload. When you try to upload an ACS or Elsevier paper now, the system checks licence status before the file goes live (C&EN, 2023).

What this means in practice: since September 2023, you cannot accidentally violate ACS or Elsevier copyright by uploading to ResearchGate. The compliance infrastructure is automated. Pre-2023 confusion is resolved.

The publisher partnerships since 2023

ResearchGate has aggressively expanded publisher partnerships through a product called Journal Home. In April 2024, the Wiley partnership expanded to 700 journals, including American Geophysical Union and Institution of Engineering and Technology society journals. Springer Nature integrated subscription content. In May 2024, PLOS joined the programme.

From a legality standpoint, ResearchGate is now in good standing with the major scholarly publishers. The question of "can I upload my paper without getting sued" is settled.

The MDPI Problem: Legal Legitimacy Is Not the Same as Reputational Legitimacy

In November 2023, ResearchGate announced a partnership with MDPI, the Swiss open-access publisher. The initial deal covered 10 journals and roughly 210,000 papers. It was later expanded to 200 journals.

MDPI is controversial. The publisher has been repeatedly criticised for rapid, low-rigour peer review, high article processing charges, and predatory-adjacent practices, though MDPI rejects these characterisations. The merits are contested. What is not contested is that a segment of the research community treated the ResearchGate-MDPI partnership as a red flag.

Social media backlash followed. Researchers on LinkedIn and on ResearchGate itself announced plans to delete accounts. A petition-style post titled "Stop the partnership between ResearchGate and MDPI!" circulated widely.

Why this matters for your account: if ResearchGate becomes increasingly populated with content from contested publishers, your paper sits alongside that content. For early-career researchers worried about credibility-by-association, that is a genuine cost, even if it is impossible to quantify precisely. It is also a cost that did not exist on the platform in 2020.

ResearchGate vs. Google Scholar: A Widely Misunderstood Question

Researchers often assume that uploading to ResearchGate will boost their Google Scholar ranking. The evidence says otherwise.

A 2021 analysis on arXiv compared ResearchGate and Google Scholar metrics directly and found that Google Scholar has higher publication and citation counts than ResearchGate in the vast majority of cases (arXiv:2105.13602). The two platforms work differently:

• Google Scholar crawls the open web, publisher pages, and institutional repositories using its own parsing algorithms.
• ResearchGate depends on user uploads and internal linking.

If your goal is Google Scholar visibility, the optimal strategy is to deposit in your institutional repository first. That repository is crawled by Google Scholar directly. ResearchGate uploads help ResearchGate's internal discoverability, but they are not the best input to Google Scholar unless the file is reachable through a crawlable URL with good metadata.

For a deeper treatment of what actually drives Google Scholar placement, see our guide on Google Scholar ranking factors.

The Honest Comparison: ResearchGate vs. the Alternatives

ResearchGate is not your only option, and it is not a substitute for several of the alternatives. The four tools serve different jobs.

The optimal stack for most biomedical researchers: ORCID (mandatory), Google Scholar profile (mandatory), institutional repository (primary discoverability), ResearchGate (secondary, for reach and paper requests). These four are not substitutes — they serve different jobs and complement each other.

What I Would Actually Recommend

Keep your ResearchGate account if:

• You are early-career and need audience reach, and your institutional repository is weak or poorly indexed
• You regularly receive meaningful paper requests through the platform
• You collaborate with researchers in regions where ResearchGate is the dominant scholarly network — notably parts of Europe, South Asia, and the Middle East, where the 2018 Iranian study found 64.5% adoption among highly-cited clinicians

Deprioritise or delete if:

• Your institutional repository is strong, well-indexed, and appears reliably in Google Scholar
• You are tenure-track and the MDPI-adjacent signal is a real concern in your field
• You never log in, never respond to paper requests, and only have an account because Google surfaced it once five years ago

Never:

• Cite your Research Interest Score in a tenure dossier — it is unvalidated
• Rely on ResearchGate as your primary path to Google Scholar indexing — it is the wrong tool
• Treat ResearchGate's internal citation counts as authoritative — use Scopus, Web of Science, or Google Scholar for any claim that matters

ResearchGate is a legitimate visibility tool with real benefits and real limitations. Neither dismiss it nor oversell it. Use it for what it is.

Methodology and Limitations of This Review

This review drew on four peer-reviewed studies retrieved from PubMed examining ResearchGate and citation outcomes; one peer-reviewed analysis of ResearchGate's scoring metrics; the public legal record of the 2017–2023 Elsevier and ACS litigation and settlement; ResearchGate's own press releases on publisher partnerships; and contemporary reporting in Nature, C&EN, Chemistry World, and Times Higher Education on the MDPI partnership backlash.

What this review cannot tell you: whether ResearchGate causes citation increases. All available evidence is correlational. A proper causal estimate would require randomising ResearchGate adoption across comparable researchers, which no one has done, and likely no one ever will. If a ResearchGate marketing page ever claims "studies show ResearchGate increases citations by X%," the correct response is to ask what "increases" means. The honest answer across all available studies is "is associated with," not "causes."